6848 related articles for article (PubMed ID: 3078572)
1. Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas.
López-Nevot MA; Garcia E; Romero C; Oliva MR; Serrano S; Garrido F
Exp Clin Immunogenet; 1988; 5(4):203-12. PubMed ID: 3078572
[TBL] [Abstract][Full Text] [Related]
2. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
3. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions.
Taramelli D; Fossati G; Mazzocchi A; Delia D; Ferrone S; Parmiani G
Cancer Res; 1986 Jan; 46(1):433-9. PubMed ID: 3079589
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens.
Ruiter DJ; Bergman W; Welvaart K; Scheffer E; van Vloten WA; Russo C; Ferrone S
Cancer Res; 1984 Sep; 44(9):3930-5. PubMed ID: 6204749
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions.
Kageshita T; Nakamura T; Yamada M; Kuriya N; Arao T; Ferrone S
Cancer Res; 1991 Mar; 51(6):1726-32. PubMed ID: 1671829
[TBL] [Abstract][Full Text] [Related]
6. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes.
Kalogeraki A; Garbagnati F; Darivianaki K; Delides GS; Santinami M; Stathopoulos EN; Zoras O
Anticancer Res; 2006; 26(5A):3551-4. PubMed ID: 17094481
[TBL] [Abstract][Full Text] [Related]
7. [Expression of HLA-class II antigens in malignant melanoma].
Nakamura T; Matsuno M; Kageshita T; Arao T
Nihon Hifuka Gakkai Zasshi; 1990 Jan; 100(1):49-56. PubMed ID: 2191157
[TBL] [Abstract][Full Text] [Related]
8. HLA expression in choroidal melanomas: correlation with clinicopathological features.
Krishnakumar S; Abhyankar D; Lakshmi SA; Pushparaj V; Shanmugam MP; Biswas J
Curr Eye Res; 2004 Jun; 28(6):409-16. PubMed ID: 15512948
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma.
Guerry D; Alexander MA; Elder DE; Herlyn MF
J Immunol; 1987 Jul; 139(1):305-12. PubMed ID: 3108402
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies.
Paul P; Cabestré FA; Le Gal FA; Khalil-Daher I; Le Danff C; Schmid M; Mercier S; Avril MF; Dausset J; Guillet JG; Carosella ED
Cancer Res; 1999 Apr; 59(8):1954-60. PubMed ID: 10213506
[TBL] [Abstract][Full Text] [Related]
11. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
[TBL] [Abstract][Full Text] [Related]
12. Surface antigenic profile of uveal melanoma lesions analysed with a panel of monoclonal antibodies directed against cutaneous melanoma.
Carrel S; Schreyer M; Gross N; Zografos L
Anticancer Res; 1990; 10(1):81-9. PubMed ID: 1692197
[TBL] [Abstract][Full Text] [Related]
13. [Expression of class II HLA antigens (HLA-DR, DQW1, DQW3) in normal skin and cutaneous pathology].
Gomes M; Schmitt D; Dezutter-Dambuyant C; Capra JD; Thivolet J
Pathol Biol (Paris); 1986 Mar; 34(3):157-64. PubMed ID: 3517784
[TBL] [Abstract][Full Text] [Related]
14. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens.
Kageshita T; Wang Z; Calorini L; Yoshii A; Kimura T; Ono T; Gattoni-Celli S; Ferrone S
Cancer Res; 1993 Jul; 53(14):3349-54. PubMed ID: 7686817
[TBL] [Abstract][Full Text] [Related]
15. Antigenic profiles of individual-matched pairs of primary and melanoma metastases.
Meije CB; Swart GW; Lepoole C; Das PK; Van den Oord JJ
Hum Pathol; 2009 Oct; 40(10):1399-407. PubMed ID: 19386352
[TBL] [Abstract][Full Text] [Related]
16. Differential susceptibility to recombinant interferon-gamma-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma.
Anichini A; Castelli C; Sozzi G; Fossati G; Parmiani G
J Immunol; 1988 Jan; 140(1):183-91. PubMed ID: 3121738
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy.
Bodey B; Kaiser HE; Goldfarb RH
Anticancer Res; 1996; 16(1):517-31. PubMed ID: 8615665
[TBL] [Abstract][Full Text] [Related]
18. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin.
Poppema S; Bröcker EB; de Leij L; Terbrack D; Visscher T; Ter Haar A; Macher E; Thé TH; Sorg C
Clin Exp Immunol; 1983 Jan; 51(1):77-82. PubMed ID: 6219841
[TBL] [Abstract][Full Text] [Related]
19. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
20. [Expression of HLA-Dr and CD1+ cells in malignant and benign pigmentary tumors].
Ramírez-Bosca A; Valcuende-Cavero F; Rufat-Pérez MJ; Castells-Rodellas A
Med Cutan Ibero Lat Am; 1989; 17(1):58-64. PubMed ID: 2474114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
